Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiaosai Yao

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Cells|July 27, 2022
Transcriptional Regulation of the Hippo Pathway: Current Understanding and Insights from Single-Cell TechnologiesSayantanee Paul, Shiqi Xie, Xiaosai Yao, et al.
Trends in Cancer|July 26, 2017
Epigenomic Consequences of Coding and Noncoding Driver MutationsXiaosai Yao, Manjie Xing, Wen Fong Ooi, et al.
International Journal of Cancer|September 22, 2010
CD8⁺ Foxp3⁺ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor responseDung T Le, Brian H Ladle, Timothy Lee, et al.
The Journal of Thoracic and Cardiovascular Surgery|August 31, 2014
Tumor cells are dislodged into the pulmonary vein during lobectomyXiaosai Yao, Christina Williamson, Viktor A Adalsteinsson, et al.
Integrative Biology : Quantitative Biosciences From Nano to Macro|September 3, 2013
Single cells from human primary colorectal tumors exhibit polyfunctional heterogeneity in secretions of ELR+ CXC chemokinesViktor A Adalsteinsson, Narmin Tahirova, Naren Tallapragada, et al.
International Journal of Cancer|June 19, 2013
Determination of 35 cell surface antigen levels in malignant pleural effusions identifies CD24 as a marker of disseminated tumor cellsXiaosai Yao, Myriam Labelle, Carla R Lamb, et al.
Nature Cancer|January 13, 2025
ERα dysfunction caused by ESR1 mutations and therapeutic pressure promotes lineage plasticity in ER<sup>+</sup> breast cancerJackson Liang, Xiaosai Yao, Patrick Aouad, et al.
Cancer Research|March 5, 2026
The Hippo Pathway is Dysregulated in Cancer-Associated Fibroblasts in Anti-PD-L1 Resistant CancerJuliette Roels, Hamid Ghaedi, Jayaram Kancherla, et al.
Cell Chemical Biology|May 20, 2026
Giredestrant immobilizes the estrogen receptor to exert potent antitumor efficacy against ER-active breast cancersWei Zhou, Musaddeque Ahmed, Jane Guan, et al.
Science Translational Medicine|September 21, 2022
Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancerJackson Liang, Ellen Rei Ingalla, Xiaosai Yao, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Cells|July 27, 2022
Transcriptional Regulation of the Hippo Pathway: Current Understanding and Insights from Single-Cell TechnologiesSayantanee Paul, Shiqi Xie, Xiaosai Yao, et al.
Trends in Cancer|July 26, 2017
Epigenomic Consequences of Coding and Noncoding Driver MutationsXiaosai Yao, Manjie Xing, Wen Fong Ooi, et al.
International Journal of Cancer|September 22, 2010
CD8⁺ Foxp3⁺ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor responseDung T Le, Brian H Ladle, Timothy Lee, et al.
The Journal of Thoracic and Cardiovascular Surgery|August 31, 2014
Tumor cells are dislodged into the pulmonary vein during lobectomyXiaosai Yao, Christina Williamson, Viktor A Adalsteinsson, et al.
Integrative Biology : Quantitative Biosciences From Nano to Macro|September 3, 2013
Single cells from human primary colorectal tumors exhibit polyfunctional heterogeneity in secretions of ELR+ CXC chemokinesViktor A Adalsteinsson, Narmin Tahirova, Naren Tallapragada, et al.
International Journal of Cancer|June 19, 2013
Determination of 35 cell surface antigen levels in malignant pleural effusions identifies CD24 as a marker of disseminated tumor cellsXiaosai Yao, Myriam Labelle, Carla R Lamb, et al.
Nature Cancer|January 13, 2025
ERα dysfunction caused by ESR1 mutations and therapeutic pressure promotes lineage plasticity in ER<sup>+</sup> breast cancerJackson Liang, Xiaosai Yao, Patrick Aouad, et al.
Cancer Research|March 5, 2026
The Hippo Pathway is Dysregulated in Cancer-Associated Fibroblasts in Anti-PD-L1 Resistant CancerJuliette Roels, Hamid Ghaedi, Jayaram Kancherla, et al.
Cell Chemical Biology|May 20, 2026
Giredestrant immobilizes the estrogen receptor to exert potent antitumor efficacy against ER-active breast cancersWei Zhou, Musaddeque Ahmed, Jane Guan, et al.
Science Translational Medicine|September 21, 2022
Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancerJackson Liang, Ellen Rei Ingalla, Xiaosai Yao, et al.
Pageof 4